Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Common Equity (2016 - 2025)

Historic Common Equity for Dr Reddys Laboratories (RDY) over the last 15 years, with Q3 2025 value amounting to $4.2 billion.

  • Dr Reddys Laboratories' Common Equity rose 1238.97% to $4.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 billion, marking a year-over-year increase of 1238.97%. This contributed to the annual value of $3.9 billion for FY2025, which is 1646.26% up from last year.
  • As of Q3 2025, Dr Reddys Laboratories' Common Equity stood at $4.2 billion, which was up 1238.97% from $3.9 billion recorded in Q1 2025.
  • Dr Reddys Laboratories' Common Equity's 5-year high stood at $4.2 billion during Q3 2025, with a 5-year trough of $2.4 billion in Q1 2021.
  • Its 5-year average for Common Equity is $3.1 billion, with a median of $2.9 billion in 2023.
  • Its Common Equity has fluctuated over the past 5 years, first soared by 420.19% in 2022, then surged by 2061.28% in 2024.
  • Over the past 5 years, Dr Reddys Laboratories' Common Equity (Quarter) stood at $2.5 billion in 2021, then increased by 4.2% to $2.6 billion in 2022, then increased by 18.36% to $3.1 billion in 2023, then increased by 20.61% to $3.7 billion in 2024, then grew by 12.39% to $4.2 billion in 2025.
  • Its Common Equity was $4.2 billion in Q3 2025, compared to $3.9 billion in Q1 2025 and $3.7 billion in Q3 2024.